A detailed history of Jane Street Group, LLC transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 25,989 shares of AADI stock, worth $74,328. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,989
Previous 134,234 80.64%
Holding current value
$74,328
Previous $195,000 72.82%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.32 - $2.06 $142,883 - $222,984
-108,245 Reduced 80.64%
25,989 $53,000
Q2 2024

Aug 14, 2024

BUY
$1.46 - $2.31 $195,981 - $310,080
134,234 New
134,234 $195,000
Q3 2023

Nov 14, 2023

BUY
$4.84 - $7.13 $51,449 - $75,791
10,630 New
10,630 $51,000
Q2 2022

Aug 16, 2022

SELL
$11.57 - $17.92 $465,495 - $720,975
-40,233 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$16.65 - $24.97 $669,879 - $1 Million
40,233 New
40,233 $683,000

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $60.1M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.